With 2020 just around the corner, let’s take a look back at our 2019!It has been a wonderful year for us here at Yuhan USA and may the next year be full of greater success.
Yuhan Corporation’s ‘IgE Trap; YH35324’ Surpasses ‘Xolair’ in Phase 1 Trials, Delivering Superior IgE Suppression in High IgE Patients (biospectator.com)
Yuhan Corporation’s ‘IgE Trap; YH35324’ Surpasses ‘Xolair’ in Phase 1 Trials, Delivering Superior IgE Suppression in High IgE Patients YH35324 is an Fc fusion protein
Yuhan
February 21, 2024